Antiplatelet use in practice by Bain, Amie
Antiplatelet use in practice 
Amie Bain, Pharmacist, Academic Practitioner and Senior Lecturer in Therapeutics, School of Applied 
Sciences, University of Huddersfield, Queensgate. Email: a.bain@hud.ac.uk 
 
Abstract  
Antiplatelets are widely used drugs that can prevent platelet activation and subsequent aggregation, 
inhibiting arterial thrombus formation that can contribute to the development of myocardial 
infarction and stroke. The use of antiplatelets for secondary prevention of cardiovascular disease is 
supported by a strong and compelling evidence base, with rigorous clinical trials supporting the use 
of varying combinations of antiplatelets for different indications. A sound understanding of how 
antiplatelets work is needed to promote their safe and effective use. This article briefly describes the 
process of platelet activation, aggregation and subsequent thrombus formation, and will discuss the 
mechanism of action of antiplatelets and their place in therapy.  
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Introduction 
Antiplatelet drugs are widely used for a number of indications, mainly involving the prevention of 
arteriothrombotic events. Most patients with established cardiovascular disease who are not already 
receiving anticoagulation therapy will be prescribed at least one antiplatelet drug, often for long-
term use. The evidence for antiplatelet use in reducing cardiovascular complications in established 
disease is compelling, and their use is strongly recommended by both national and international 
bodies for patients with established cardiovascular disease. A sound understanding of both how 
antiplatelets work and the evidence for their indicated uses can help practitioners improve patient 
knowledge, acceptance and adherence to this important class of medication. The current article 
briefly describes the process of platelet activation, aggregation and subsequent thrombus formation 
that results in cardiovascular events, and discusses the mechanism of action of antiplatelets, as well 
as their place in therapy.  
 
Role of platelets  
Platelets are essential components of haemostasis and pathological thrombus formation, and work 
to maintain the integrity of the circulation (Kroll, 1998). Following vessel injury, the vascular 
endothelium is breached, exposing subendothelial proteins such as von Willebrand factor (vWF) and 
collagen to blood (Gale, 2011). These proteins stick to glycoprotein receptors (e.g. Ib and VI) which 
are expressed on the surface of platelets. As a result, platelets adhere both to the vessel at the site 
of injury and to each other, forming a platelet plug (Golebiewska and Poole, 2015).  
This adhesion then leads to platelet activation as well as the formation and upregulation of platelet 
glycoprotein IIb/IIIa receptor complexes; the platelets change shape and release pro-aggregating 
factors (e.g. thromboxane A2, which is synthesised from arachidonic acid by COX–1), contributing to 
further aggregation. Fibrinogen in the plasma then crosslinks glycoprotein IIb/IIIa receptors on the 
platelets, causing irreversible aggregation (Figure 1).  
Various physiological mechanisms regulate this process, including endothelium-derived prostacyclin 
(prostaglandin I2/PGI2) and nitric oxide, which inhibit platelet adhesion and activation (Waller and 
Sampson, 2017). This normal physiological process of platelet adhesion and activation can aid 
processes such as wound healing and the repair of ruptured atherosclerotic plaques. However, when 
it is uncontrolled—which may happen in the presence of vessel disease such as atherosclerosis and 
endothelial damage—it can lead to thrombus formation, vessel occlusion and ischaemia/infarction.  
To reduce the risk of unwanted pathology, it is sometimes necessary to use antiplatelet drugs to 
interfere with the platelet aggregation process. Antiplatelets decrease platelet aggregation and/or 
subsequent activation, and inhibit thrombus formation—particularly in the arterial circulation where 
thrombi are mainly composed of platelets, as opposed to the venous circulation where thrombi are 
mainly composed of fibrin (Previtali et al, 2011).  
There are a variety of drugs in this class, with individual agents targeting different parts of the 
platelet aggregation process to reduce the risk of thrombus formation. Examples of how different 
antiplatelet agents work are given in the next section.  
 
 
Mechanism of action  
Antiplatelet drugs can either block pro-aggregation and activation mechanisms, or mimic 
endogenous inhibitory mechanisms. For example, the glycoprotein IIb/IIIa receptor complex is the 
final common step in the processes of thrombus formation, whereby conformational changes allow 
for cross-linking via fibrinogen. By interfering with the formation, upregulation and function of this 
receptor complex, platelet aggregation can be limited. 
Thromboxane A2 (TXA2) is a pro-aggregation mediator that activates platelets and upregulates 
glycoprotein IIb/IIIa receptors. Inhibiting the synthesis and action of TXA2 will therefore inhibit 
platelet activation and aggregation. The most commonly used antiplatelet—aspirin—may exert its 
action by inhibiting COX–1, the enzyme that catalyses production of TXA2 from arachidonic acid. 
Because platelets have no nucleus, they are unable to regenerate once damaged. The antiplatelet 
effect therefore lasts the lifetime of the platelet (around 10 days), and is complete when 75–150 mg 
is given once daily. Adherence to daily aspirin treatment is important, as regularly missing doses will 
compromise its antithrombotic protection. 
 Adenosine diphosphate (ADP) is another pro-aggregating factor that contributes to platelet 
activation, and glycoprotein IIb/IIIa receptor formation and upregulation. Drugs that block ADP 
receptors on platelets (e.g. P2Y12 receptors) such as clopidogrel, prasugrel, ticagrelor and cangrelor, 
can therefore inhibit platelet aggregation and activation. Ticagrelor and prasugrel have a more rapid 
onset of action and less interpatient variability than clopidogrel (Jernberg et al, 2006; Wallentin et al, 
2009), but have fewer licensed indications.  
Glycoprotein IIb/IIIa receptors can also be downregulated by agents that mimic endogenous 
inhibitory mediators such as PGI2; dipyridamole and epoprostenol, for example, increase the 
concentration of platelet cAMP (dipyridamole inhibits the reuptake of adenosine, which stimulates 
production of intracellular adenylyl cyclase)—an endogenous cyclic nucleotide that inhibits the 
activation of glycoprotein IIb/IIIa receptors on the platelet (Waller and Sampson, 2017: 171–173).  
Abciximab, tirofiban and eptifibatide are examples of glycoprotein IIb/IIIa receptor antagonists that 
act on the final step of platelet aggregation: they bind to the receptor complex, blocking fibrinogen 
from attaching and binding platelets together (Rang et al, 2012). Abciximab is a monoclonal 
antibody, whereas tirofiban and eptifibatide are small molecule glycoprotein inhibitors which have a 
quicker offset of action.  
Because multiple signalling pathways are involved in platelet activation and aggregation, 
antiplatelets that target different elements of the platelet aggregation process are often used in 
combination to maximise the overall antiplatelet effect (Table 1). In practice, this almost always 
consists of using aspirin in combination with another antiplatelet (e.g. a P2Y12 inhibitor); this is 
often referred to as dualantiplatelet therapy (DAPT). The need for combination therapy will depend 
on the patient and the indication(s), but general recommendations based on national guidance are 
outlined below.  
 
Indications  
The end result of uncontrolled platelet aggregation is the formation of a blood clot—a thrombus. 
Thrombi can occlude blood vessels, causing blood flow to be obstructed and consequential 
ischaemia to tissue (Golebiewska and Poole, 2015). When pieces of thrombi become detached and 
travel through the circulation, lodging somewhere else to cause an obstruction, it is known as an 
embolus (hence the term thromboembolic disease). As platelet-rich thrombi are typically found in 
arteries, antiplatelet agents are mostly used to treat conditions that arise as a result of blood clots in 
the arterial circulation.  
Acute coronary syndrome (ACS), for example, occurs as a result of thrombus formation in the 
coronary arteries, leading to ischaemic damage. Long-term antiplatelet therapy is recommended in 
all patients after an episode of ACS, including ST–elevated myocardial infarction (STEMI), non–ST 
elevation myocardial infarction (NSTEMI) and unstable angina, to prevent further platelet 
aggregation and thrombus formation (National Institute for Health and Care Excellence (NICE), 
2013a; 2013b). In practice, this is often DAPT consisting of long-term aspirin 75 mg daily, with the 
addition of a P2Y12 antagonist (e.g. ticagrelor or clopidogrel) for 12 months (Table 2). The use of 
DAPT allows for the prevention of further thrombus formation at the site of endothelial damage, as 
well as supporting endothelialisation in patients who have had a stent fitted. In addition, P2Y12 
inhibitor therapy helps to reduce the likelihood of stent thrombosis in patients who undergo 
coronary artery stent implantation, a rare but potentially fatal complication of percutaneous 
coronary intervention (PCI). 
Other examples of arterial thromboembolic disease include ischaemic stroke and transient ischaemic 
attack (TIA). Here, thrombi obstruct blood flow in arteries in the brain (e.g. the middle cerebral 
artery) with subsequent ischaemia. Patients who have experienced an ischaemic stroke or a TIA will 
routinely be offered long-term antiplatelet therapy to reduce the risk of further platelet aggregation 
and repeat episodes (Intercollegiate Stroke Working Party, 2016). The exception to this is if atrial 
fibrillation (AF) is also present, and there is no other indication for DAPT. In this case, after the acute 
phase, an anticoagulant (e.g. warfarin, apixaban, rivaroxaban, dabigatran or edoxaban) will be 
offered instead of an antiplatelet because they are significantly more effective in patients with AF 
(Aguilar et al, 2007). If both DAPT and anticoagulation are indicated (e.g. if a patient has a history of 
AF-related stroke and recent myocardial infarction (MI)) and used concomitantly, the duration of 
DAPT treatment is usually shortened to mitigate against bleeding risk as assessed using the HAS–
BLED risk score. 
Although antiplatelets are recommended for secondary prevention of thromboembolic events in 
people with established ischaemic cardiovascular or cerebrovascular disease, they are not generally 
recommended for primary prevention as the risk of bleeding outweighs therapeutic benefit (Perk et 
al, 2012; Scottish Intercollegiate Guidelines Network (SIGN), 2013). For individuals at risk (e.g. in 
those with hypertension and renal impairment), expert opinion varies, with weak evidence leading 
some clinicians to prescribe aspirin 75 mg daily for primary prevention (Nansseu and Noubiap, 
2015), despite its unlicensed indication.  
Antiplatelets can also be used during or following angioplasty/PCI with stenting and coronary artery 
bypass grafts (CABG) to prevent reocclusion or restenosis of the affected vessel(s). They may also be 
used for peripheral arterial disease, including carotid artery disease and peripheral artery disease 
(Table 2). 
 
The evidence  
The value of antiplatelets for secondary prevention of cardiovascular and cerebrovascular disease is 
well-established. For patients at high risk, taking long-term antiplatelet therapy has been shown to 
reduce the combined outcome of non-fatal MI, non-fatal stroke or vascular death by about 25% 
(Antithrombotic Trialists’ Collaboration, 2002). For ACS, various trials have proven the benefit of 
antiplatelet therapy for secondary prevention. Aspirin is the oldest and most widely used 
antiplatelet, with the ISIS–2 trial (ISIS–2 (Second International Study of Infarct Survival) Collaborative 
Group, 1988) demonstrating its benefit regarding short- and long-term mortality (both vascular and 
all-cause), and morbidity (i.e. reinfarction). When clopidogrel is added to aspirin, there is a further 
reduction in cardiovascular mortality, non-fatal MI and stroke, as demonstrated in the CURE and 
COMMIT trials (Yusuf et al, 2001; Chen et al, 2005), although this increases major and minor 
bleeding risk. 
The TRITON-TIMI-38 trial (Wiviott et al, 2007) demonstrated the benefits of prasugrel over 
clopidogrel with respect to reduction in cardiovascular morbidity and mortality (although it 
increased bleeding) in the event of ACS scheduled for PCI. The TRILOGY-ACS trial (Roe et al, 2012) 
did not find the same benefits in patients with ACS who were not scheduled for revascularisation. 
More recently, the PLATO trial demonstrated a significant reduction in composite death from 
vascular causes, MI or stroke with no difference in major or severe bleeding when ticagrelor was 
used instead of clopidogrel (Wallentin et al, 2009). This trial directed the European Society of 
Cardiology (ESC) to recommended ticagrelor as the P2Y12 inhibitor of choice in combination with 
aspirin for ACS in its guidelines (Roffi et al, 2016).  
For stable angina, aspirin is the most cost-effective antiplatelet. The CAPRIE trial (CAPRIE Steering 
Committee, 1996) showed that clopidogrel is as effective as aspirin in reducing the risk of vascular 
events (MI, stroke and vascular death), so can be used in patients who cannot tolerate aspirin. 
Subgroup analyses have demonstrated the benefit of clopidogrel over aspirin in both peripheral 
arterial disease and multivessel disease, making it the drug of choice for these indications (NICE, 
2018).  
In the event of ischaemic stroke, the use of aspirin was shown to reduce mortality and improve 
functional recovery by 2.7% when given within 48 hours of symptom onset (after haemorrhagic 
stroke has been ruled out) in the CAST and IST trials (Chen et al, 2000). When used in the long term, 
aspirin can reduce the likelihood of stroke recurrence by up to 23%. Clopidogrel can reduce this risk 
by a further 8% when used alone, but increases the risk of life-threatening bleeding when used with 
aspirin (Walker and Whittlesea, 2012: 153). Aspirin and dipyridamole are currently recommended by 
NICE for TIA because clopidogrel is not licensed for TIA (NICE, 2010). However, this combination is no 
better than clopidogrel monotherapy (Sacco et al, 2008), which is recommended in both stroke and 
TIA by the Intercollegiate Stroke Working Party (2016). Current recommendations for the above 
indications are summarised in Table 2. 
Side-effects and interactions 
Most antiplatelets are associated with an increased risk of haemorrhage, which is greater at higher 
maintenance doses (e.g. aspirin after CABG or to treat pain in certain circumstances), when 
antiplatelets are used in combination or in situations necessitating the use of an antiplatelet with an 
anticoagulant (e.g. aspirin and warfarin). For patients, this might mean an increased propensity to 
bruise easily, and cuts and grazes may take longer to stop bleeding than usual; however, unless 
bleeding is profuse and/or protracted, this is not usually a cause for concern.  
Aspirin is associated with a high incidence of gastrointestinal side-effects. This is because it inhibits 
COX–1, which prevents the production of prostaglandins, leading to a reduction in the secretion of 
mucus that would otherwise coat the lining of the stomach to protect it from acidic contents. 
Inhibition therefore depletes the protective layer and exposes the stomach lining to the acidic 
content therein, causing dyspepsia-like symptoms. It is recommended that aspirin should be taken 
with or after food to minimise this effect (Lanas and Scheiman, 2007). In some individuals at risk of 
these complications (e.g. those with a history of dyspepsia), a proton pump inhibitor (PPI) (e.g. 
lansoprazole) can be prescribed concomitantly, or clopidogrel could be used instead. 
Gastrointestinal complications are not reduced when enteric coated aspirin is used (Kelly et al, 
1996), so it is not routinely prescribed.  
Clopidogrel is metabolised by the CYP2C19 enzyme, giving rise to potential interactions with some 
other drugs such as omeprazole, fluconazole and carbamazepine, which may compromise its 
antiplatelet activity. Ticagrelor is a CYP3A4 inhibitor so should be avoided (or used very cautiously) 
with concomitant clarithromycin, digoxin or simvastatin. Increased monitoring, reviewed doses or 
alternative agents may be recommended for these cases. 
 
Contraindications and cautions  
The use of antiplatelets in the presence of pathological bleeding (e.g. peptic ulcer or intracranial 
haemorrhage) or haemorrhagic disorders (e.g. thrombocytopenia) is contraindicated. Antiplatelets 
should be discontinued around a week before certain surgical or invasive diagnostic procedures if an 
antiplatelet effect is not desirable, and should be prescribed alongside other agents that predispose 
to bleeding (e.g. NSAIDS and SSRIs) with caution.  
Prasugrel should not be given to patients who have had a stroke or TIA because of the increased risk 
of fatal bleeding, and requires dose adjustment based on age and weight (Table 2). Because 
dipyridamole has vasodilator properties, it can worsen migraine symptoms, and should also be used 
with caution in severe coronary heart disease, heart failure and myasthenia gravis. Patients who 
have respiratory disease should be given aspirin or P2Y12 inhibitors with caution, because they have 
the side-effects of bronchospasm and dyspnoea respectively (although this does not usually lead to 
discontinuation). To manage these potential interactions, monitoring may be increased, and 
alternative agents offered if necessary.  
 
Conclusion  
The use of antiplatelet drugs, alone or in combination, is widespread among patients with 
cardiovascular disease. Evidence for the use of antiplatelets in secondary prevention is substantial, 
and they are generally safe and effective. Practitioners need a sound understanding of both how 
antiplatelets work and the evidence for their indicated uses to improve patient knowledge, 
acceptance and adherence to this class of drug. 
 
Key Points   
Antiplatelet drugs are widely used to prevent complications in established cardiovascular disease. 
A variety of antiplatelet drugs are available; they target different parts of the platelet aggregation 
process to reduce the risk of thrombus formation. 
Common indications for antiplatelet therapy include secondary prevention of acute coronary 
syndrome and non-AF-related ischaemic stroke, as well as peripheral arterial disease and stable 
angina. 
Although commonly used, antiplatelet therapy is not without risk. Interacting medications, side-
effects, bleeding risk and past medical history should all be considered when using antiplatelet 
agents in practice 
 
CPD Reflection Questions 
How would you describe the action of antiplatelets to patients in your setting?  
What factors need to be considered before prescribing antiplatelets to patients?  
What information is important to communicate to patients in order to promote the safe and 
effective use of antiplatelets? 
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